Lycken Magdalena, Bergengren Oskar, Drevin Linda, Garmo Hans, Westerberg Marcus, Axén Elin, Stranne Johan, Holmberg Lars, Bill-Axelson Anna
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Uppsala Örebro Regional Cancer Centre, Uppsala, Sweden.
Eur Urol Open Sci. 2022 May 28;41:81-87. doi: 10.1016/j.euros.2022.05.003. eCollection 2022 Jul.
Attempts to reduce prostate cancer (PC) mortality require an understanding of temporal changes in the characteristics of men with lethal PC.
To describe the diagnostic characteristics of and time trends for a nationwide population-based cohort of Swedish men who died from PC between 1992 and 2016.
Men with PC as the underlying cause of death from 1992 to 2016 according to the Swedish Cause of Death Register were included in the study. Characteristics at diagnosis were collected via links to other nationwide registries using personal identity numbers.
Data on disease duration, age at death, and risk category were analyzed. Missing data for risk categories for men with an early date of PC diagnosis were imputed according to the method of chained equations.
Between 1992 and 2016, age-standardized PC mortality decreased by 25%. Median PC disease duration increased from 3.3 yr (interquartile range [IQR] 1.6-6.3) to 5.9 yr (IQR 2.5-10.3) and the median age at death from PC increased from 78.9 yr (IQR 73.3-84.2) to 82.2 yr (IQR 75.2-87.5). The proportion of men with localized disease at diagnosis who died from PC increased from 34% to 48%, while the rate of distant metastases at diagnosis decreased from 56% to 42%. The rate of distant metastases at diagnosis was highest among the youngest men. Treatment trajectories could not be described owing to the large proportion of missing data before the start of registration in the National Prostate Cancer Registry.
Age-standardized PC mortality has decreased substantially since 1992. However, there is still a high proportion of men who die from PC who had localized disease at diagnosis, which indicates that more attention is needed to identify the underlying causes to prevent disease progression. Since the proportion of men with distant metastases at diagnosis remains high, early detection of lethal tumors is essential to further reduce PC mortality.
We investigated the characteristics of men who died from prostate cancer in Sweden between 1992 and 2016. We found that men with lethal prostate cancer live longer and are older when they die today in comparison to men who died at the beginning of the study period. However, the proportion of men with distant metastases at diagnosis remains high, which is why early detection of lethal tumors is essential to reduce mortality.
降低前列腺癌(PC)死亡率的努力需要了解致命性PC男性患者特征的时间变化。
描述1992年至2016年间瑞典全国范围内因PC死亡的男性人群队列的诊断特征和时间趋势。
设计、设置和参与者:根据瑞典死亡原因登记册,纳入1992年至2016年间以PC为根本死因的男性。诊断时的特征通过使用个人身份号码链接到其他全国性登记册来收集。
分析疾病持续时间、死亡年龄和风险类别的数据。PC诊断日期较早的男性风险类别的缺失数据根据链式方程法进行插补。
1992年至2016年间,年龄标准化的PC死亡率下降了25%。PC疾病的中位持续时间从3.3年(四分位间距[IQR]1.6 - 6.3)增加到5.9年(IQR 2.5 - 10.3),PC死亡的中位年龄从78.9岁(IQR 73.3 - 84.2)增加到82.2岁(IQR 75.2 - 87.5)。诊断时患有局限性疾病且死于PC的男性比例从34%增加到48%,而诊断时远处转移的比例从56%下降到42%。诊断时远处转移的比例在最年轻的男性中最高。由于国家前列腺癌登记册登记开始前缺失数据的比例很大,无法描述治疗轨迹。
自1992年以来,年龄标准化的PC死亡率大幅下降。然而,诊断时患有局限性疾病且死于PC的男性比例仍然很高,这表明需要更多关注以确定预防疾病进展的潜在原因。由于诊断时伴有远处转移的男性比例仍然很高,早期发现致命性肿瘤对于进一步降低PC死亡率至关重要。
我们调查了1992年至2016年间瑞典死于前列腺癌的男性的特征。我们发现,与研究初期死亡的男性相比,患有致命性前列腺癌的男性如今存活时间更长且死亡时年龄更大。然而诊断时伴有远处转移的男性比例仍然很高,这就是早期发现致命性肿瘤对于降低死亡率至关重要的原因。